37,850 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Entropy Technologies LP

Entropy Technologies LP purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, HoldingsChannel.com reports. The firm purchased 37,850 shares of the biotechnology company’s stock, valued at approximately $757,000.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in ADMA Biologics during the 2nd quarter worth $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the 3rd quarter worth $30,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter worth $31,000. CWM LLC lifted its stake in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter worth $93,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on ADMA shares. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The trade was a 10.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Stock Down 5.9 %

Shares of NASDAQ ADMA opened at $20.20 on Friday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64. The firm has a 50-day moving average price of $18.42 and a 200 day moving average price of $14.22. The stock has a market capitalization of $4.71 billion, a price-to-earnings ratio of 72.14 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period last year, the firm posted $0.01 EPS. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.